scholarly journals Comparison of Point-of-Care Testing and Hospital-Based Methods in Screening for Potential Type 2 Diabetes Mellitus and Abnormal Glucose Regulation in a Dental Setting

Author(s):  
Muneedej Suwattipong ◽  
Thitima Thuramonwong ◽  
Chanita Tantipoj ◽  
Pornpoj Fuangtharnthip ◽  
Supanee Thanakun ◽  
...  

This study aimed to compare the screening methods between point-of-care (POC) testing and hospital-based methods for potential type 2 DM and abnormal glucose regulation (AGR) in a dental setting. A total of 274 consecutive subjects who attended the Faculty of Dentistry, Mahidol University, Bangkok, Thailand, were selected. Demographic data were collected. HbA1c was assessed using a finger prick blood sample and analyzed with a point-of-care (POC) testing machine (DCA Vantage®). Hyperglycemia was defined as POC HbA1c ≥ 5.7%. Random blood glucose (RBG) was also evaluated using a glucometer (OneTouch® SelectSimple™) and hyperglycemia was defined as RBG ≥ 110 mg/dl or ≥140 mg/dl. The subjects were then sent for laboratory measurements for fasting plasma glucose (FPG) and HbA1c. The prevalence of AGR (defined as FPG ≥ 100 mg/dl or laboratory HbA1c ≥ 5.7%) and potential type 2 DM (defined as FPG ≥ 126 mg/dl or laboratory HbA1c ≥ 6.5%) among subjects was calculated and receiver operating characteristic (ROC) analysis was performed using FPG and HbA1c for the diagnosis of AGR and potential type 2 DM. The prevalence of hyperglycemia defined as POC HbA1c ≥ 5.7%, RBG ≥ 110 mg/dl, and RBG ≥ 140 mg/dl was 49%, 63%, and 32%, respectively. After the evaluation using laboratory measurements, the prevalence of AGR was 25% and 17% using laboratory FPG and HbA1c criteria, respectively. Based on the ROC curves, the performances of POC HbA1c and RBG in predicting FPG-defined potential type 2 DM were high (AUC = 0.99; 95% CI 0.98–0.99 and AUC = 0.94; 95% CI 0.86–1.0, respectively) but lower in predicting AGR (AUC = 0.72; 95% CI 0.67–0.78 and AUC = 0.65; 95% CI 0.59–0.70, respectively). This study suggested that POC testing might be a potential tool for screening of subjects with potential type 2 DM in a dental setting.

2011 ◽  
Vol 18 (03) ◽  
pp. 430-435
Author(s):  
K.M. YAHYA ◽  
KHALID IQBAL ◽  
HUMA YAHYA

Background: Type-2 DM is an epidemic globally and is the major heath problem. Public awareness has lead to increased screening and treatments. But unfortunately, control is very poor overall. People get treatment but do not check the advantages of treatment. Objectives: To see the success and accuracy of treatment of DM, this study was conducted. Diabetic control was assessed by HBA1C level. Design: Prospective study. Setting: Department of Medicine OPD of All major Hospitals Faisalabad. Period: From 01-03-2009 to 14-05-2009. Methods: This multicentric was carried out in different hospitals of Faisalabad. Total of 67 patients of both sexes and different age groups with Type-2 DM were evaluated for primary goal of control of DM by measuring HBA1C with point of care (POC) technology. Various secondary features ware also noted. Results: Total n = 67 males = 38 females = 29. Study revealed a poor control in all patients. Mean HBA1C in male was 85% and in female 87%. There were differences in HBA1C as regards to level of education, socio-economic status but there was no difference with regard to truncal obesity & type of transport used. Conclusions: DM control was very poor in all groups with respect to age, sex, and type of treatment. This is a matter of concern both to the patient and their attending physicians. Poor control has far reaching implications to the patients, society, and the family.


2019 ◽  
Author(s):  
Olufolake Olabode ◽  
Timothy Omoluru ◽  
Olawunmi Olagundoye ◽  
Akinyele Akinlade ◽  
Henry Akujobi ◽  
...  

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 952-P
Author(s):  
MANOJ S. CHAWLA ◽  
PURVI M. CHAWLA ◽  
MIKHIL C. KOTHARI ◽  
AMBARI F. SHAIKH ◽  
NAVNEET WADHWA

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 740-P
Author(s):  
MARGARET ZUPA ◽  
MICHELE HEISLER ◽  
JOHN PIETTE ◽  
RANAK B. TRIVEDI ◽  
SHELLEY C. STOLL ◽  
...  

2021 ◽  
Author(s):  
David Cate ◽  
Helen Hsieh ◽  
Veronika Glukhova ◽  
Joshua D Bishop ◽  
H Gleda Hermansky ◽  
...  

<p></p><p>The global COVID-19 pandemic has created an urgent demand for large numbers of inexpensive, accurate, rapid, point-of-care diagnostic tests. Analyte-based assays are suitably inexpensive and can be rapidly mass-produced, but for sufficiently accurate performance they require highly optimized antibodies and assay conditions. We used an automated liquid handling system, customized to handle arrays of lateral flow immunoassay (LFA) tests in a high-throughput screen, to identify anti-nucleocapsid antibodies that will perform optimally in an LFA. We tested 1021 anti-nucleocapsid antibody pairs as LFA capture and detection reagents with the goal of highlighting pairs that have the greatest affinity for unique epitopes of the nucleocapsid protein of SARS-CoV-2 within the LFA format. In contrast to traditional antibody screening methods (e.g., ELISA, bio-layer interferometry), the method described here integrates real-time reaction kinetics with transport in, and immobilization directly onto, nitrocellulose. We have identified several candidate antibody pairs that are suitable for further development of an LFA for SARS-CoV-2.</p><p></p>


Sign in / Sign up

Export Citation Format

Share Document